Search for content, post, videos

Elicera Therapeutics files a patent application

patent

Elicera Therapeutics has filed a patent application to protect the development of its drug candidate ELC-201.

ELC-201 is the second oncolytic virus in Elicera Therapeutic’s product portfolio. It is based on an adenovirus that has been genetically modified in a way that makes the treatment applicable to most cancers and the patent application protects the application of two more genetic modifications in combination that together give the drug candidate three mechanisms of action.

In addition to ELC-201, Elicera is also developing ELC-100, an oncolytic virus developed for the treatment of neuroendocrine tumors. ELC-100 is currently in an ongoing Phase I / II clinical trial.

Photo: iStock